This hypothesis is plausible considering that it is well established that EGFR-mutant NSCLC patients have different sensitivity to targeted therapies according to the exon in which the original sensitizing mutation is detected [27]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.